Table 2.
Absolute BMD and percentage change from baseline in patients randomized to ZA or placebo at 24 and 52 wk
| BMD in g/cm2 (sd)
|
% Change in BMD (sem)
|
||||||
|---|---|---|---|---|---|---|---|
| Baseline | 1 yr | 2 yr | P value | 1 yr | 2 yr | P value | |
| LS | |||||||
| Placebo | 1.071 (0.12) | 1.020 (0.13) | 1.011 (0.14) | <0.001a | −5.4 (0.55) | −6.3 (0.83) | <0.001a |
| ZA | 1.036 (0.12) | 1.048 (0.13) | 1.028 (0.12) | <0.001b | 1.3 (0.58) | −0.6 (0.84) | NSb |
| FN | |||||||
| Placebo | 0.864 (0.13) | 0.860 (0.13) | 0.854 (0.14) | 0.09a | −1.5 (0.61) | −2.4 (0.71) | 0.05a |
| ZA | 0.830 (0.13) | 0.843 (0.13) | 0.842 (0.13) | 0.10b | 1.1 (0.42) | 0.04 (0.84) | NSb |
| TH | |||||||
| Placebo | 0.988 (0.11) | 0.984 (0.14) | 0.978 (0.14) | 0.002a | −1.9 (0.66) | −2.6 (0.84) | <0.001a |
| ZA | 0.946 (0.11) | 0.955 (0.11) | 0.962 (0.10) | <0.001b | 0.7 (1.06) | 0.8 (1.07) | NSb |
NS, Not significant.
a
P value for the comparison of the difference between treatment group means ignoring time.
b
P value for the comparison of treatment group differences in their pattern of change over time.